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eativecommons.org/licenses/by-nc-Summary There are estimated to be more than a hundred million hepatitis C virus (HCV) car-
riers worldwide. About 30% of carriers develop serious liver diseases, such as liver cirrhosis and
hepatocellular carcinoma. HCV Genotype 1 is the most common genotype worldwide and the
most difficult to treat with interferon-based therapy. Therapy for patients with chronic HCV
infection is complicated by poor tolerability and inadequate rates of sustained virological
response (SVR). Although the addition of a protease inhibitor in combination with peg-
interferon alpha plus ribavirin improved SVR rates and shortened the treatment period,many pa-
tients could not tolerate this therapy because of advanced age and clinical conditions such as
anemia and low platelet count. Interferon-free therapies that combine two or more direct-
acting antiviral (DAA) agents can improve both efficacy and tolerability. Phase III trials of dacla-
tasvir plus asunaprevir, ombitasvir plus parataprevir/r, and sofosbuvir plus ledipasvir all showed
high overall SVR rates with few adverse events. However, development of antiviral resistance is a
concern with DAA therapies, and it is important to avoid treating patients with existing NS5A
Y93H mutations with daclatasvir plus asunaprevir or ombitasvir plus parataprevir/r therapy to
prevent viral breakthrough. Fortunately, sofosbuvir plus ledipasvir therapy seems to be less
affected by NS5A Y93H variants. An important goal of HCV therapy is to expand treatment to
all patients. The current study aims to show the efficacy and safety of these therapies both in
clinical trial and real world settings based on our own clinical experiences.
Copyright ª 2016, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society
of Taiwan and Taiwan Association for the Study of the Liver. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).t of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical & Health
Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
a-u.ac.jp (K. Chayama).
6.03.002
roenterological Society of Taiwan, The Digestive Endoscopy Society of Taiwan and Taiwan Association
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
nd/4.0/).
154 K. Chayama et al.Introduction
Epidemiology
Hepatitis C virus (HCV) is a major public health challenge
throughout the world, and there are estimated to be at least
185million HCV carriers worldwide [1,2]. In Japan the rate of
chronic HCV infection is estimated to be up to 2% of the
population, and Japanese patients are more likely to be
older and female with prior treatment experience and more
advanced liver disease than patients in western countries
[3]. Although frequencies of the six HCV genotypes vary
geographically, HCV Genotype 1 is the most common geno-
type worldwide and is among the most difficult to treat with
interferon therapy. Failure to clear the virus increases the
risk of severe liver disease, and up to 30% of carriers develop
liver cirrhosis or hepatocellular carcinoma (HCC). The goal of
HCV therapy is sustained virological response (SVR), defined
as continuously undetectable HCV ribonucleic acid (RNA)
levels 12 weeks (SVR12) or 24 weeks (SVR24) after the end of
therapy. However, the risk of cirrhosis and HCC remains high
even among patients who achieve SVR, although effective
treatment is thought to reduce the risk of HCC [4]. There-
fore, early identification and effective treatment of patients
with chronic HCV is a high priority.
Until recently, peg-interferon plus ribavirin combination
therapy was the standard of care for treatment of HCV
Genotype 1. Under this demanding treatment, weekly in-
jections with peg-interferon and daily dosing of ribavirin
continued for 48 weeks, with possible extension to 72
weeks in slow responders. However, older patients or pa-
tients with cirrhosis or other contra-indications were inel-
igible, and even among eligible patients, expected SVR
rates remained below 50%. While some patients responded
transiently to treatment, other patients failed to respond
and showed no change in HCV RNA levels. Due to poor
tolerability and low rates of SVR with interferon therapy, a
novel approach was urgently needed.
Direct acting antivirals
Despite its potent antiviral effects, interferon has only
limited specificity against HCV, mediated through a large set
of interferon-stimulated genes that establish a general
antiviral state, and the virus has evolved mechanisms to
disrupt interferon signaling in hepatocytes and impede the
innate immune response. Patients with specific single
nucleotide polymorphisms have also been shown to respond
poorly to interferon therapy. The next advance in HCV
therapy was the development of direct-acting antivirals
(DAAs), which strongly inhibit replication of HCV by directly
targeting essential viral proteins. High-throughput methods
are used to screen candidate drugs, followed by lead opti-
mization. Four main classes of DAAs have been developed so
far that target three different viral proteins: NS3/4A prote-
ase inhibitors, NS5A inhibitors, and two types of NS5B poly-
merase inhibitors [5]. In 2011, the protease inhibitors
telaprevir and boceprevir were the first DAAs to be approved
for clinical use in the form of a triple therapy in combination
with peg-interferon and ribavirin. Telaprevir triple therapy
not only increased the SVR rate to 70e80%, but alsoshortened treatment duration [6,7]. However, these im-
provements were not without cost, and severe adverse
events including rash and anemia further restricted patient
eligibility and led to frequent dose reductions and discon-
tinuation. Fortunately, telaprevir and boceprevir have been
largely superseded by second wave and second generation
protease inhibitors with improved tolerability. Triple ther-
apy with simeprevir [8] or vaniprevir [9] is currently used in
Japan for treatment of Genotype 1 chronic HCV infection.
Interferon-free therapy
Interferon-free therapies that combine two or more DAAs
promise improved efficacy and tolerability over interferon-
based DAA therapies. The role played by interferon and
ribavirin in triple therapy is partly to suppress selection for
DAA resistant variants. In order to provide equivalent pro-
tection without interferon, DAAs belonging to two or more
DAA classes with nonoverlapping resistance profiles are
combined to increase the overall barrier to resistance. Phase
III trials of daclatasvir plus asunaprevir, ombitasvir plus
parataprevir/r, and sofosbuvir plus ledipasvir have shown
high overall SVR rates with few adverse events. Several DAA
combination therapies have recently been approved in
Japan. Daclatasvir plus asunaprevir therapy [10] and sofos-
buvir plus ledipasvir [11] have been approved for treatment
of Genotype 1 infection, and sofosbuvir plus ribavirin has
been approved for treatment of Genotype 2 infection [12].
Antiviral resistance
The high rate of HCV replication combined with the low fi-
delity of HCV polymerase leads to rapid emergence of single
and double point mutations throughout the HCV genome and
the maintenance of multiple HCV quasispecies. The efficacy
of a specific DAA combination therapy depends on the
effectiveness of each coadministered DAA. Emergence of
resistance to one class of DAA increases the selective pres-
sure of the remaining DAAs and increases the probability of
viral breakthrough. While emergence of resistance-
associated variants (RAVs) during therapy in a subset of pa-
tients due to chance may be unavoidable, ineffective
treatment of patients with preexisting variants can be
avoided through screening. Genotype 1a has a lower genetic
barrier to resistance to several protease inhibitors at R155
than Genotype 1b, which partly explains differences in
approved treatments between the United States and Japan,
where Genotype 1b is more prevalent [13]. The simeprevir-
resistant Q80K mutation also occurs more frequently in pa-
tients with HCV Genotype 1a, suggesting that screening for
the Q80 mutation should be considered for Genotype 1a
patients prior to simeprevir therapy and an alternative
therapy prepared if necessary. However, a number of DAA-
treatment-naive Japanese patients have been found to
harbor preexisting NS5A Y93H variants, which can confer
resistance to NS5A inhibitors. Treatment of patients with
existing NS5A Y93H variants can lead to viral breakthrough
during daclatasvir plus asunaprevir or ombitasvir plus para-
taprevir/r therapy. In contrast to other treatment-emergent
RAVs, which tend to have low fitness in competition with
wild-type strains and are quickly lost after cessation of
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drug, which may confound future retreatment efforts with
similar drugs. Fortunately, combination therapy with sofos-
buvir and ledipasvir appears to be less affected by NS5AY93H
variants and may provide an alternative retreatment option
for these patients. Nonetheless, these considerations un-
derscore the need for increased screening and monitoring of
resistance during the transition to interferon-free therapies.
Asunaprevir plus daclatasvir dual therapy
Asunaprevir plus daclatasvir dual therapy was the first
approved interferon-freeDAA therapy. The therapy combines
asunaprevir, an NS3/4A protease inhibitor, with daclatasvir,
an NS5A inhibitor [14,15]. In a Phase II study in the United
States, Genotype 1 patients were treated with daclatasvir
and asunaprevir with or without peg-interferon and ribavirin
for 24 weeks and achieved SVR12 rates of 78% for daclatasvir
plus asunaprevir alone and 95% in four-way combination with
peg-interferon and ribavirin [15]. In a Phase III study in Japan,
222 HCV Genotype 1 patients who were poor candidates for
interferon therapywere treated for 24weekswithdaclatasvir
and asunaprevir [10]. Eighty-seven percent of patients who
were ineligible for interferon treatment achieved SVR24, and
81% of patients who had failed to respond to prior interferon
therapy achieved SVR24. Ninety-one percent of patients with
cirrhosis and 84% of patients without cirrhosis achieved
SVR24.Thirteenpercentofpatientsdiscontinuedtherapydue
to poor response or adverse events such as alanine trans-
aminase (ALT) or aspartate transaminase (AST) elevation,
headache, or nasopharyngitis. This study demonstrated high
SVR rates in distinct difficult-to-treat populations and showed
that SVR24 rates were not affected by treatment history or
baseline factors affecting response to interferon therapy,
including sex, age, baseline HCV RNA levels, cirrhosis, and
IFNL3 single nucleotide polymorphism genotype. A recent
randomized Phase III clinical trial by Kumada et al [16]
compared daclatasvir/asunaprevir dual therapy to
telaprevir/peg-interferon/ribavirin triple therapy in
treatment-naive Genotype 1b patients in Japan. Patients
treated with daclatasvir plus asunaprevir achieved higher
SVR12 rates (89%) than patients treated with telaprevir triple
therapy (62%) and experienced markedly lower incidence of
adverse events, especially with respect to drug discontinua-
tion, rash,anemiaandGrade3or4adverseevents.A separate
cohort of prior relapsers treated with asunaprevir and
daclatasvir achieved a 95% SVR rate. The HALLMARK DUAL
Phase III study showed similar results with SVR12 rates of 90%
among treatment-naive patients and 82% among interferon-
intolerant patients or prior null/partial responders [17].
While the Food and Drug Administration (FDA) initially
approved daclatasvir for use in combination with sofosbuvir
for treatment of Genotype 3 in July 2015, they expanded
approval for daclatasvir plus sofosbuvir for treatment of Ge-
notypes 1 and 3 in February 2016.
Asunaprevir plus daclatasvir plus beclabuvir triple
therapy
An extension of dual DAA therapy is the addition of a third
DAA to simultaneously target three viral proteins andincrease the genetic barrier to resistance. Beclabuvir is a
nonnucleoside inhibitor targeting the thumb 1 domain NS5B
RNA dependent RNA polymerase. The drug has exhibited
antiviral activity in vitro against Genotypes 1, 3, 4, 5, and 6
[18], and patients treated for 12 or 24 weeks with beclabuvir
in combination with daclatasvir and asunaprevir achieved a
92% SVR rate in a Phase II clinical trial [19]. In the open-label
dual-arm UNITY-2 study, patients with cirrhosis were treated
with asunaprevir, daclatasvir, and beclabuvir with orwithout
ribavirin for 12 weeks [20]. In the ribavirin group, 98% of
treatment-naive patients achieved SVR12, and 93% of
treatment-experienced patients achieved SVR, whereas 93%
and 87% of patients, respectively, achieved SVR12 in the
nonribavirin group. Compared to nucleoside inhibitors like
sofosbuvir, however, nonnucleoside inhibitors have a rela-
tively lower barrier to resistance, and NS5B A421 and P495
variants have been observed to confer resistance to becla-
buvir [21,22]. However, in a replicon study in which no
inhibitory effect was observed for daclatasvir and asunap-
revir alone against NS5A L31M/Y93H double mutants, the
addition of beclabuvir effectively suppressed HCV replica-
tion [23], suggesting a potential role for beclabuvir in
retreating daclatasvir and asunaprevir nonresponders.
UNITY 3 (NCT02123654), a Phase III clinical trial examining
the efficacy of daclatasvir plus asunaprevir plus beclabuvir
therapy in Japan, is ongoing.
Sofosbuvir plus ledipasvir
Although triple DAA therapy is attractive in principle, the
combination of three drugs increases the costs and limits
opportunity for retreatment in the event of emergence of
multidrug resistance. In another dual DAA approach, an
NS5A inhibitor such as daclatasvir or ledipasvir is combined
with an NS5B polymerase inhibitor such as sofosbuvir. In a
Phase III open label study of treatment-naive Genotype 1
patients randomly assigned to ledipasvir and sofosbuvir
combination therapy with or without ribavirin for 12 or 24
weeks, 96% of patients achieved SVR12 after 12 weeks of
therapy and 99% achieved SVR12 after 24 weeks of therapy
[24,25]. In a related Phase III study, prior nonresponders
(including nonresponders to prior telaprevir triple therapy)
treated with sofosbuvir plus ledipasvir achieved SVR rates
of 94% and 99% after 12 and 24 weeks of therapy, respec-
tively [24]. In a Phase III study examining shorter treatment
duration, 94% of noncirrhotic treatment-naive patients
achieved SVR12 after 8 weeks and 95% after 12 weeks [26].
The FDA approved Gilead’s HARVONI (ledipasvir co-
formulated with sofosbuvir) for Genotype 1 in October
2014 and granted approval for Genotypes 4, 5, and 6 in
November 2015.
Paritaprevir/ritonavir, ombitasvir, and dasabuvir
Although many of the competing DAAs reported in early
stages of development have since been discontinued, the
combination of paritaprevir with ritonavir (ABT-450/r, a
protease inhibitor), ombitasvir (ABT-267, an NS5A inhibi-
tor), and dasabuvir (ABT-333, a non-nucleoside NS5B poly-
merase inhibitor), with or without ribavirin, has emerged as
an alternative to sofosbuvir/ledipasvir and asunaprevir/
Table 1 Characteristics of patients treated with dacla-
tasvir and asunaprevir at Hiroshima University Hospital.
Male/female 86/114
Age, y (range) 74.4 (36e88)
Treatment history
Treatment-naı¨ve 68
Interferon therapy 109
Telaprevir þ PegIFN/RBV 12
Simeprevir þ PegIFN/RBV 2
Liver cirrhosis 66
Baseline resistance-associated variants
HCV NS3 D168 (wild/mutant)a 198/0
HCV NS5A L31, Y93 (wild/mutant)a 163/35
Post liver transplantation 7
Hemodialysis patients 3
HCV Z hepatitis C virus; PegIFN/RBV Z peg-interferon plus
ribavirin.
a Detected by either direct sequencing or PCR-Invader assay.
Figure 1 Frequency of naturally occurring (preexisting) HCV
NS5A Y93H substitutions in patients treated with daclatasvir
plus asunaprevir therapy. Patients with Y93H substitutions
>91% were not treated with daclatasvir plus asunaprevir.
HCV Z hepatitis C virus.
156 K. Chayama et al.daclatasvir therapies in both the United States and Japan.
AbbVie’s Viekira Pak (coformulated ombitasvir/par-
itaprevir/ritonavir and dasabuvir tablets) was approved in
the United States in December 2014, and VIEKIRAX (par-
itaprevir/ritonavir coformulated with ombitasvir) was
approved in Japan in September 2015. In a Phase III clinical
trial, treatment-naive patients treated with paritaprevir/r,
ombitasvir, dasabuvir, and ribavirin for 12 weeks achieved
an SVR12 rate of 98% in Genotype 1b patients and 95% in
Genotype 1a patients [27]. In another Phase III trial, 99.5%
of Genotype 1b patients and 97% of Genotype 1a patients
achieved SVR12 [28]. In the Phase III GIFT-1 clinical trial in
Japan, 94% of noncirrhotic patients and 91% of cirrhotic
patients achieved SVR12 [29]. In a Phase III trial examining
prior treatment history, 96% of prior nonresponders ach-
ieved SVR after 12 weeks of paritaprevir/r, ombitasvir,
dasabuvir, and ribavirin therapy. In a Phase III clinical trial
examining treatment duration in patients with compen-
sated cirrhosis, 91% of patients achieved SVR after 12 weeks
of therapy, and 96% of patients achieved SVR after 24 weeks
of therapy. However, the FDA recently issued a warning
concerning treatment of cirrhotic patients after reports of
serious liver injury or death, indicating that treatment of
cirrhotic patients is not without risk.
Grazoprevir plus elbasvir
Despite issues with toxicity, genotype specificity, and high
cross-resistance associated with early protease inhibitors,
development of second generation protease inhibitors such
as grazoprevir is expected to provide pan-genotypic activity
as well as improved resistance profiles. Grazoprevir exhibits
SVR rates ranging from 89 to 100% and is insensitive to most
RAVs affecting first generation protease inhibitors [30]. In
the Phase II C-WORTHY clinical trial, treatment-naive HCV
Genotype 1 patients treated with grazoprevir plus elbasvir
(an NS5A inhibitor) with or without ribavirin for 12 weeks
achieved a 93% SVR rate [31]. Another C-WORTHY study
examining treatment duration in prior null responders
demonstrated SVR12 rates up to 100% after 18 weeks of
grazoprevir, elbasvir, and ribavirin treatment [32].
Clinical trials and real world DAA treatment
outcomes at Hiroshima University Hospital
Since approval of the treatment in 2014, we have treated
over 200 patients with asunaprevir plus daclatasvir therapy
at Hiroshima University Hospital (Table 1). Fifty-seven
percent of patients have been female, and patients have
ranged in age from 36 to 88 years old with a mean age of
74.4. Thirty-four percent of patients were treatment-naive,
while 54% had received prior interferon therapy. Another 12
patients had previously been treated with telaprevir triple
therapy, and two patients had been treated with simeprevir
triple therapy. Thirty-three percent of patients have
cirrhosis, and three patients have undergone hemodialysis.
Seven patients had received liver transplantation prior to
asunaprevir plus daclatasvir therapy. All patients were
wild-type for HCV NS3 D168, but 17.5% of patients had
varying mixtures of mutant and wild-type amino acids for
HCV NS5A L31 and Y93 (Figure 1). The presence of baselineNS3 and NS5A variants was determined either by nested PCR
followed by the Invader assay [33] or by direct sequencing
or deep sequencing.
Despite the variability of this patient population, 90% of
patients achieved SVR following 24 weeks of asunaprevir
plus daclatasvir therapy, while six patients experienced
viral breakthrough or relapse (Table 2). The SVR rate was
low among patients with preexisting NS5A Y93H and/or
NS5A L31V/A RAVs, and on-treatment emergence of NS5A
L31/Y93 and NS3 D168 variants was associated with treat-
ment failure [4]. In a population sequencing study of 30
patients in a Phase III clinical trial at Hiroshima University,
patients with wild type NS5A L31 and Y93 were significantly
more likely to achieve SVR. While all patients with wild
type NS5A achieved SVR, only 44% of patients with NS5A
L31M or Y93H/F substitutions achieved SVR (Figure 2A).
After declining sharply and remaining undetectable during
the first weeks of therapy, HCV RNA levels rebounded
rapidly to pretreatment levels in some patients with NS5A
Table 2 Characteristics of patients who experienced
treatment failure under asunaprevir plus daclatasvir
therapy.a
Age Sex Previous
DAA treatment
NS3
D168
NS5A
L31
NS5A
Y93
Outcome
72 M d Wildb L31Mb Wildb Breakthrough
74 M SMV/IFN/RBV Wildc Wild Wild Breakthrough
66 F SMV/IFN/RBV Wild Wild Wild Breakthrough
66 F d Wild Wild Wild Breakthrough
65 F d Wild Wild Wild Breakthrough
65 M d Wild Wild Wild Relapse
DAA Z direct-acting antiviral; SMV/IFN/RBV Z simeprevir plus
peg-interferon plus ribavirin triple therapy; Wild Z wild-type
amino acid.
a Presence of preexisting NS3 and NS5A resistance-associated
variants was determined by PCR-Invader assay unless otherwise
noted.
b Direct sequencing.
c Deep sequencing.
All-oral HCV treatment 157L31M or Y93H/F substitutions (Figures 2B and 2C). Figure 3
shows changes in the frequencies of HCV NS3 D168 and NS5A
L31/Y93 during treatment and follow-up in a patient who
experienced viral breakthrough during asunaprevir plus
daclatasvir therapy during a Phase III clinical trial at Hir-
oshima University. While HCV NS3 D168V/A variants
emerged during viral breakthrough, they were replaced byFigure 2 Outcome of daclatasvir plus asunaprevir therapy stratifi
clinical trial at Hiroshima University. Amino acid sequences of L
determined by population sequencing. (A) SVR rate following dacl
substitutions; (B) time course of HCV RNA levels in patients with wi
of HCV RNA levels in patients with preexisting NS5A L31M and/or Y9
acid; SVR Z sustained virological response.wild type after treatment discontinuation. On the other
hand, in addition to the patient’s preexisting Y93H substi-
tution, an L31M/I substitution emerged at the time of viral
breakthrough, and both variants persisted stably at >99%
throughout the follow-up period.
While asunaprevir plus daclatasvir therapy is contra-
indicated for patients with high pretreatment frequencies
of RAVs, patients with relatively low frequencies of natu-
rally occurring drug resistance mutations are nonetheless
candidates for real world asunaprevir plus daclatasvir
therapy. High SVR rates were achieved both for patients
with wild type NS5A (96.5%) as well as those with NS5A L31M
or Y93H/F substitutions (93.5%) in our real world experi-
ences with asunaprevir plus daclatasvir therapy so far
(Figure 4).
Eight patients with HCV infection after liver trans-
plantation were treated with daclatasvir plus asunaprevir
therapy. Figure 5 showed the changes of serum HCV RNA
levels of the eight patients. Although one patient with prior
simeprevir treatment failure developed viral breakthrough,
the remaining seven patients achieved SVR. All patients
received tacrolimus for immunosuppression. During the
combination treatment, the changes of trough blood con-
centration of tacrolimus were minimal. No particular
adverse events were observed during the therapy.
Daclatasvir and asunaprevir are metabolized in the liver
and excreted through the bile ducts. Thus, combination
therapy with these drugs does not seem to adversely affect
renal function. The SVR rate of daclatasvir and asunaprevired by presence of baseline NS5A substitutions during a Phase III
31 and Y93 before daclatasvir plus asunaprevir therapy were
atasvir plus asunaprevir therapy with respect to baseline NS5A
ld type HCV NS5A L31 and Y93 amino acids; and (C) time course
3H/F substitutions. HCVZ hepatitis C virus; RNAZ ribonucleic
Figure 3 Time course of changes in HCV, NS3, D168, and NS5A L31 and Y93 substitutions in a 75 year old female who experienced
viral breakthrough during daclatasvir (DCV) plus asunaprevir (ASV) therapy in a Phase III clinical trial at Hiroshima University. HCV
variants were determined by deep sequencing. HCV Z hepatitis C virus.
Figure 4 Real world SVR24 rates at Hiroshima University
following daclatasvir plus asunaprevir therapy in treatment-
naı¨ve patients with wild type or L31M and/or Y93H/F NS5A
substitutions. Patients with relatively low frequencies of NS5A
resistance associated variants were candidates for real world
asunaprevir plus daclatasvir therapy. High SVR rates were
achieved for both patients with wild type NS5A as well as those
with NS5A L31M or Y93H/F substitutions. HCV variants were
determined by population sequencing. HCV Z hepatitis C
virus; SVR Z sustained virological response.
158 K. Chayama et al.for patients with renal dysfunction (estimated glomerular
filtration rate [eGFR] < 50 mL/min/1.73m2]) was similar to
that of patients with normal renal function (eGFR  50 mL/
min/1.73m2) (Figure 6). The frequency of adverse events
such as ALT elevation was also similar between the two
groups.
Based on response to asunaprevir and daclatasvir ther-
apy to date, we conclude that SVR rates approaching 90%
can be achieved and that liver transplant recipients and
patients with renal failure can be safely treated. However,
SVR rates were low among patients with baseline or
treatment-emergent Y93H or L31V/A substitutions, and
patients with preexisting NS5A substitutions or who have
experienced prior simeprevir plus peg-interferon plus
ribavirin treatment failure should avoid treatment with
asunaprevir plus daclatasvir. Care should be taken to
monitor ALT elevation, although elevated ALT levels may
decline rapidly after cessation of therapy. Ledipasvir plus
sofosbuvir combination therapy may be effective for
retreatment of patients who experience asunaprevir plus
daclatasvir treatment failure.Conclusion
Although the pace of entry of new DAAs into clinical testing
may have peaked, a diverse set of DAAs have now been
approved in the United States, Japan, and elsewhere, and a
number of promising dual and triple DAA therapies are
being evaluated in Phase III clinical trials. Antiviral resis-
tance remains a potentially worrying but manageable
Figure 5 Changes in HCV RNA levels in eight patients treated with daclatasvir plus asunaprevir following liver transplantation.
Although viral breakthrough occurred in one patient who had previously experienced simeprevir treatment failure, the other seven
patients achieved SVR (upper panel). No adverse events were observed during therapy, and changes in trough blood concentrations
were minimal (lower panel). HCV Z hepatitis C virus; RNA Z ribonucleic acid; SVR Z sustained virological response.
Figure 6 SVR rates in patients with respect to renal function.
The SVR rate did not differ significantly between patients with
renal dysfunction (right; eGFR < 50 mL/min/1.73m2) compared
with patients with normal renal function (left; eGFR  50 mL/
min/1.73m2). eGFR Z estimated glomerular filtration rate;
ns Z not significant; SVR Z sustained virological response.
All-oral HCV treatment 159problem, although the long-term implications of DAA
resistance are difficult to predict. Pretreatment screening
of NS3/4A or NS5A RAVs is advisable prior to simeprevir or
daclatasvir therapy, respectively, and on-treatment moni-
toring should be used to detect treatment-emergent RAVs,although effective monitoring might await wide-spread
adoption of simple and cost-effective RAV detection
methods [33]. In principle, nearly all patients should now
be eligible for HCV therapy and have excellent prospects
for achieving SVR, but in practice some patients with unmet
needs await further advances in the treatment of chronic
HCV.
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